鲁丁 (II) 聚烯基复合物通过刺激免疫系统以增加CD8+T细胞来抑制瘤生长
Shuang Tian1, Haixin Xu1, Xiaoyu Wu2
1School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510006, PR China.
European journal of medicinal chemistry
|March 7, 2025
概括
两个新型的 (Ruthenium) 复合物,6a和6b通过诱导亡和铁亡,对HepG2细胞表现出强烈的抗癌活性. 复合物6a通过激活免疫反应显著抑制了小鼠的瘤生长.
科学领域:
- 协调化学 协调化学
- 材料科学 材料科学 材料科学
- 癌症研究 癌症研究
背景情况:
- 开发用于癌症治疗的新型金属复合物.
- 需要具有明确作用机制的向抗癌药物.
- 探索 (II) 复合物的细胞毒性特性.
研究的目的:
- 合成和表征两个新的鲁 (II) 复合物,即[鲁 (二) ] (HMPIP) ] (PF6) 2 (6a) 和[鲁 (bpy) ] (HMPIP) ] (PF6) 2 (6b).
- 评估复合物6a和6b对HepG2癌细胞的体外和体内抗癌功效.
- 阐明作用的潜在机制,包括亡,铁亡和免疫反应调节.
主要方法:
- 合成和表征Ru (II) 复合物.
- 在体外细胞毒性测定使用MTT对各种癌细胞系 (HepG2,B16,A549,SGC-7901,HCT116) 和非癌细胞系 (LO2) 进行检测.
- 细胞循环分析,细胞吸收研究,细胞灭亡试验,自评估,氧化还原稳态评估 (GSH,GPX4,MDA) 和BODIPY染色.
- 在裸体小鼠模型中进行体内瘤抑制研究.
- 对免疫反应标记物 (TNF-α,IFN-γ,IL-10,CD8+ T细胞) 和信号通路 (PI3K/AKT/mTOR) 的分析.
主要成果:
- 这两种复合物都对HepG2细胞表现出显著的细胞毒性.
- 复合体6a和6b诱导了HepG2细胞中的G0/G1细胞周期停止,细胞亡和铁亡.
- 复合物6a在裸体小鼠模型中表现出显著的体内瘤生长抑制 (63.4%的抑制),没有任何不良影响,同时激活了免疫系统.
- 机理学研究显示了氧化还原稳定性,线粒体通路干扰和PI3K/AKT/mTOR信号抑制的破坏.
结论:
- (II) 复合物6a和6b是具有多方面的作用机制的强有力的抗癌剂.
- 复合物6a通过直接细胞毒性和免疫调节,对HepG2瘤具有显著的治疗潜力.
- 这些Ru (II) 复合物代表了作为抗癌疗法进一步开发的有希望的候选人.
更多相关视频
相关概念视频
Tumor Immunotherapy
457
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
457
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Cytotoxic T Cells-mediated Immune Response
825
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
825
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K


